CONCORD, Mass.--(BUSINESS WIRE)-- Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
June 2021 Price Concessions 1st Update
Widely used non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of heart failure - even in people without a history of cardiac issues, a recent study suggests.
If you’re one of an estimated 27 million Americans with osteoarthritis, you might think it makes sense to try Tylenol 8 Hour Arthritis Pain caplets to relieve your aching hips or knees.